James C. Ballenger

Title
InstitutionMedical University of South Carolina
DepartmentPsychiatry and Behavioral Sciences
Address
vCardDownload vCard

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. George MS, Ward HE, Ninan PT, Pollack M, Nahas Z, Anderson B, Kose S, Howland RH, Goodman WK, Ballenger JC. A pilot study of vagus nerve stimulation (VNS) for treatment-resistant anxiety disorders. Brain Stimul. 2008 Apr; 1(2):112-21. PMID: 20633378.
      Citations:    
    2. Post RM, Ketter TA, Uhde T, Ballenger JC. Thirty years of clinical experience with carbamazepine in the treatment of bipolar illness: principles and practice. CNS Drugs. 2007; 21(1):47-71. PMID: 17190529.
      Citations:    
    3. Weisler RH, Cutler AJ, Ballenger JC, Post RM, Ketter TA. The use of antiepileptic drugs in bipolar disorders: a review based on evidence from controlled trials. CNS Spectr. 2006 Oct; 11(10):788-99. PMID: 17008822.
      Citations:    
    4. Lorberbaum JP, Kose S, Johnson MR, Arana GW, Sullivan LK, Hamner MB, Ballenger JC, Lydiard RB, Brodrick PS, Bohning DE, George MS. Neural correlates of speech anticipatory anxiety in generalized social phobia. Neuroreport. 2004 Dec 22; 15(18):2701-5. PMID: 15597038.
      Citations:    
    5. Ballenger JC. Remission rates in patients with anxiety disorders treated with paroxetine. J Clin Psychiatry. 2004 Dec; 65(12):1696-707. PMID: 15641876.
      Citations:    
    6. Ballenger JC, Davidson JR, Lecrubier Y, Nutt DJ, Marshall RD, Nemeroff CB, Shalev AY, Yehuda R. Consensus statement update on posttraumatic stress disorder from the international consensus group on depression and anxiety. J Clin Psychiatry. 2004; 65 Suppl 1:55-62. PMID: 14728098.
      Citations:    
    7. Roy-Byrne P, Russo J, Pollack M, Stewart R, Bystrisky A, Bell J, Rosenbaum J, Corrigan MH, Stolk J, Rush AJ, Ballenger J. Personality and symptom sensitivity predictors of alprazolam withdrawal in panic disorder. Psychol Med. 2003 Apr; 33(3):511-8. PMID: 12701671.
      Citations:    
    8. Simon NM, Emmanuel N, Ballenger J, Worthington JJ, Kinrys G, Korbly NB, Farach FJ, Pollack MH. Bupropion sustained release for panic disorder. Psychopharmacol Bull. 2003; 37(4):66-72. PMID: 15131517.
      Citations:    
    9. Nutt DJ, Ballenger JC, Sheehan D, Wittchen HU. Generalized anxiety disorder: comorbidity, comparative biology and treatment. Int J Neuropsychopharmacol. 2002 Dec; 5(4):315-25. PMID: 12466031.
      Citations:    
    10. Malcolm R, Myrick H, Roberts J, Wang W, Anton RF, Ballenger JC. The effects of carbamazepine and lorazepam on single versus multiple previous alcohol withdrawals in an outpatient randomized trial. J Gen Intern Med. 2002 May; 17(5):349-55. PMID: 12047731.
      Citations:    
    11. Pellegrin KL, Stuart GW, Maree B, Frueh BC, Ballenger JC. A brief scale for assessing patients' satisfaction with care in outpatient psychiatric services. Psychiatr Serv. 2001 Jun; 52(6):816-9. PMID: 11376232.
      Citations:    
    12. Ballenger JC, Davidson JR, Lecrubier Y, Nutt DJ. A Proposed Algorithm for Improved Recognition and Treatment of the Depression/Anxiety Spectrum in Primary Care. Prim Care Companion J Clin Psychiatry. 2001 Apr; 3(2):44-52. PMID: 15014615.
      Citations:    
    13. Ballenger JC, Davidson JR, Lecrubier Y, Nutt DJ, Roose SP, Sheps DS. Consensus statement on depression, anxiety, and cardiovascular disease. J Clin Psychiatry. 2001; 62 Suppl 8:24-7. PMID: 12108818.
      Citations:    
    14. Ballenger JC. Overview of different pharmacotherapies for attaining remission in generalized anxiety disorder. J Clin Psychiatry. 2001; 62 Suppl 19:11-9. PMID: 11577786.
      Citations:    
    15. Ballenger JC, Davidson JR, Lecrubier Y, Nutt DJ, Kirmayer LJ, Lépine JP, Lin KM, Tajima O, Ono Y. Consensus statement on transcultural issues in depression and anxiety from the International Consensus Group on Depression and Anxiety. J Clin Psychiatry. 2001; 62 Suppl 13:47-55. PMID: 11434419.
      Citations:    
    16. Ballenger JC. Treatment of anxiety disorders to remission. J Clin Psychiatry. 2001; 62 Suppl 12:5-9. PMID: 11430617.
      Citations:    
    17. Ballenger JC, Davidson JR, Lecrubier Y, Nutt DJ, Jones RD, Berard RM. Consensus statement on depression, anxiety, and oncology. J Clin Psychiatry. 2001; 62 Suppl 8:64-7. PMID: 12108825.
      Citations:    
    18. Ballenger JC, Davidson JR, Lecrubier Y, Nutt DJ, Lydiard RB, Mayer EA. Consensus statement on depression, anxiety, and functional gastrointestinal disorders. J Clin Psychiatry. 2001; 62 Suppl 8:48-51. PMID: 12108822.
      Citations:    
    19. Ballenger JC, Davidson JR, Lecrubier Y, Nutt DJ, Borkovec TD, Rickels K, Stein DJ, Wittchen HU. Consensus statement on generalized anxiety disorder from the International Consensus Group on Depression and Anxiety. J Clin Psychiatry. 2001; 62 Suppl 11:53-8. PMID: 11414552.
      Citations:    
    20. Malcolm R, Myrick H, Brady KT, Ballenger JC. Update on anticonvulsants for the treatment of alcohol withdrawal. Am J Addict. 2001; 10(s1):s16-s23. PMID: 11268817.
      Citations:    
    21. Frueh BC, Deitsch SE, Santos AB, Gold PB, Johnson MR, Meisler N, Magruder KM, Ballenger JC. Procedural and methodological issues in telepsychiatry research and program development. Psychiatr Serv. 2000 Dec; 51(12):1522-7. PMID: 11097648.
      Citations:    
    22. George MS, Sackeim HA, Marangell LB, Husain MM, Nahas Z, Lisanby SH, Ballenger JC, Rush AJ. Vagus nerve stimulation. A potential therapy for resistant depression? Psychiatr Clin North Am. 2000 Dec; 23(4):757-83. PMID: 11147246.
      Citations:    
    23. Ballenger JC. Structural issues and policy in the management of depressive illness. Overview and expert panel commentary. Eur Neuropsychopharmacol. 2000 Dec; 10 Suppl 4:S449-53. PMID: 11114491.
      Citations:    
    24. George MS, Nahas Z, Molloy M, Speer AM, Oliver NC, Li XB, Arana GW, Risch SC, Ballenger JC. A controlled trial of daily left prefrontal cortex TMS for treating depression. Biol Psychiatry. 2000 Nov 15; 48(10):962-70. PMID: 11082469.
      Citations:    
    25. George MS, Nahas Z, Bohning DE, Lomarev M, Denslow S, Osenbach R, Ballenger JC. Vagus nerve stimulation: a new form of therapeutic brain stimulation. CNS Spectr. 2000 Nov; 5(11):43-52. PMID: 18188148.
      Citations:    
    26. Ballenger JC. Recognizing the patient with social anxiety disorder. Int Clin Psychopharmacol. 2000 Jul; 15 Suppl 1:S1-5. PMID: 10994676.
      Citations:    
    27. Ballenger JC. Anxiety and Depression: Optimizing Treatments. Prim Care Companion J Clin Psychiatry. 2000 Jun; 2(3):71-79. PMID: 15014652.
      Citations:    
    28. George MS, Sackeim HA, Rush AJ, Marangell LB, Nahas Z, Husain MM, Lisanby S, Burt T, Goldman J, Ballenger JC. Vagus nerve stimulation: a new tool for brain research and therapy. Biol Psychiatry. 2000 Feb 15; 47(4):287-95. PMID: 10686263.
      Citations:    
    29. Emmanuel NP, Brawman-Mintzer O, Morton WA, Book SW, Johnson MR, Lorberbaum JP, Ballenger JC, Lydiard RB. Bupropion-SR in treatment of social phobia. Depress Anxiety. 2000; 12(2):111-3. PMID: 11091936.
      Citations:    
    30. Ballenger JC, Davidson JR, Lecrubier Y, Nutt DJ, Foa EB, Kessler RC, McFarlane AC, Shalev AY. Consensus statement on posttraumatic stress disorder from the International Consensus Group on Depression and Anxiety. J Clin Psychiatry. 2000; 61 Suppl 5:60-6. PMID: 10761680.
      Citations:    
    31. Ballenger JC. Current treatments of the anxiety disorders in adults. Biol Psychiatry. 1999 Dec 01; 46(11):1579-94. PMID: 10599485.
      Citations:    
    32. Greenberg PE, Sisitsky T, Kessler RC, Finkelstein SN, Berndt ER, Davidson JR, Ballenger JC, Fyer AJ. The economic burden of anxiety disorders in the 1990s. J Clin Psychiatry. 1999 Jul; 60(7):427-35. PMID: 10453795.
      Citations:    
    33. George MS, Tenebäck CC, Malcolm RJ, Moore J, Stallings LE, Spicer KM, Anton RF, Ballenger JC. Multiple previous alcohol detoxifications are associated with decreased medial temporal and paralimbic function in the postwithdrawal period. Alcohol Clin Exp Res. 1999 Jun; 23(6):1077-84. PMID: 10397294.
      Citations:    
    34. Emmanuel NP, Ware MR, Brawman-Mintzer O, Ballenger JC, Lydiard RB. Once-weekly dosing of fluoxetine in the maintenance of remission in panic disorder. J Clin Psychiatry. 1999 May; 60(5):299-301. PMID: 10362436.
      Citations:    
    35. Ballenger JC, Davidson JR, Lecrubier Y, Nutt DJ, Goldberg D, Magruder KM, Schulberg HC, Tylee A, Wittchen HU. Consensus statement on the primary care management of depression from the International Consensus Group on Depression and Anxiety. J Clin Psychiatry. 1999; 60 Suppl 7:54-61. PMID: 10326875.
      Citations:    
    36. Lorberbaum JP, Newman JD, Dubno JR, Horwitz AR, Nahas Z, Teneback CC, Bloomer CW, Bohning DE, Vincent D, Johnson MR, Emmanuel N, Brawman-Mintzer O, Book SW, Lydiard RB, Ballenger JC, George MS. Feasibility of using fMRI to study mothers responding to infant cries. Depress Anxiety. 1999; 10(3):99-104. PMID: 10604082.
      Citations:    
    37. Ballenger JC. Clinical guidelines for establishing remission in patients with depression and anxiety. J Clin Psychiatry. 1999; 60 Suppl 22:29-34. PMID: 10634353.
      Citations:    
    38. Ballenger JC. Translational implications of the amygdala-stria terminalis model for the clinical anxiety disorders. Biol Psychiatry. 1998 Dec 15; 44(12):1204-7. PMID: 9861462.
      Citations:    
    39. Labbate LA, Johnson MR, Lydiard RB, Brawman-Mintzer O, Emmanuel N, Crawford M, Kapp R, Ballenger JC. Sleep Deprivation in social phobia and generalized anxiety disorder. Biol Psychiatry. 1998 Jun 01; 43(11):840-2. PMID: 9611674.
      Citations:    
    40. Ballenger JC. Comorbidity of panic and depression: implications for clinical management. Int Clin Psychopharmacol. 1998 Apr; 13 Suppl 4:S13-7. PMID: 9690960.
      Citations:    
    41. Ballenger JC, Wheadon DE, Steiner M, Bushnell W, Gergel IP. Double-blind, fixed-dose, placebo-controlled study of paroxetine in the treatment of panic disorder. Am J Psychiatry. 1998 Jan; 155(1):36-42. PMID: 9433336.
      Citations:    
    42. Ballenger JC. Treatment of panic disorder in the general medical setting. J Psychosom Res. 1998 Jan; 44(1):5-15. PMID: 9483459.
      Citations:    
    43. Ballenger JC, Davidson JR, Lecrubier Y, Nutt DJ, Baldwin DS, den Boer JA, Kasper S, Shear MK. Consensus statement on panic disorder from the International Consensus Group on Depression and Anxiety. J Clin Psychiatry. 1998; 59 Suppl 8:47-54. PMID: 9707162.
      Citations:    
    44. Ballenger JC, Davidson JR, Lecrubier Y, Nutt DJ, Bobes J, Beidel DC, Ono Y, Westenberg HG. Consensus statement on social anxiety disorder from the International Consensus Group on Depression and Anxiety. J Clin Psychiatry. 1998; 59 Suppl 17:54-60. PMID: 9811431.
      Citations:    
    45. Labbate LA, Johnson MR, Lydiard RB, Brawman-Mintzer O, Emmanuel N, Crawford M, Kapp R, Ballenger JC. Sleep deprivation in panic disorder and obsessive-compulsive disorder. Can J Psychiatry. 1997 Nov; 42(9):982-3. PMID: 9429072.
      Citations:    
    46. Hollifield M, Katon W, Skipper B, Chapman T, Ballenger JC, Mannuzza S, Fyer AJ. Panic disorder and quality of life: variables predictive of functional impairment. Am J Psychiatry. 1997 Jun; 154(6):766-72. PMID: 9167503.
      Citations:    
    47. Brawman-Mintzer O, Lydiard RB, Bradwejn J, Villarreal G, Knapp R, Emmanuel N, Ware MR, He Q, Ballenger JC. Effects of the cholecystokinin agonist pentagastrin in patients with generalized anxiety disorder. Am J Psychiatry. 1997 May; 154(5):700-2. PMID: 9137133.
      Citations:    
    48. Ballenger JC. Discussion and overview: what can we learn if we view panic disorder across the life span and across different presentations and contexts? Bull Menninger Clin. 1997; 61(2 Suppl A):A95-102. PMID: 9149467.
      Citations:    
    49. Ballenger JC. Panic disorder in the medical setting. J Clin Psychiatry. 1997; 58 Suppl 2:13-7; discussion 18-9. PMID: 9078989.
      Citations:    
    50. Lydiard RB, Ballenger JC, Rickels K. A double-blind evaluation of the safety and efficacy of abecarnil, alprazolam, and placebo in outpatients with generalized anxiety disorder. Abecarnil Work Group. J Clin Psychiatry. 1997; 58 Suppl 11:11-8. PMID: 9363043.
      Citations:    
    51. Irwin C, Falsetti SA, Lydiard RB, Ballenger JC, Brock CD, Brener W. Comorbidity of posttraumatic stress disorder and irritable bowel syndrome. J Clin Psychiatry. 1996 Dec; 57(12):576-8. PMID: 9010120.
      Citations:    
    52. Lydiard RB, Brawman-Mintzer O, Ballenger JC. Recent developments in the psychopharmacology of anxiety disorders. J Consult Clin Psychol. 1996 Aug; 64(4):660-8. PMID: 8803355.
      Citations:    
    53. Ballenger JC. Clinical evaluation of venlafaxine. J Clin Psychopharmacol. 1996 Jun; 16(3 Suppl 2):29S-35S; discussion 35S-36S. PMID: 8784646.
      Citations:    
    54. Fossey MD, Lydiard RB, Ballenger JC, Laraia MT, Bissette G, Nemeroff CB. Cerebrospinal fluid corticotropin-releasing factor concentrations in patients with anxiety disorders and normal comparison subjects. Biol Psychiatry. 1996 Apr 15; 39(8):703-7. PMID: 8731457.
      Citations:    
    55. Katschnig H, Amering M, Stolk JM, Ballenger JC. Predictors of quality of life in a long-term followup study in panic disorder patients after a clinical drug trial. Psychopharmacol Bull. 1996; 32(1):149-55. PMID: 8927665.
      Citations:    
    56. Fyer AJ, Katon W, Hollifield M, Rassnick H, Mannuzza S, Chapman T, Ballenger JC. The DSM-IV panic disorder field trial: panic attack frequency and functional disability. Anxiety. 1996; 2(4):157-66. PMID: 9160617.
      Citations:    
    57. Brawman-Mintzer O, Lydiard RB, Phillips KA, Morton A, Czepowicz V, Emmanuel N, Villareal G, Johnson M, Ballenger JC. Body dysmorphic disorder in patients with anxiety disorders and major depression: a comorbidity study. Am J Psychiatry. 1995 Nov; 152(11):1665-7. PMID: 7485632.
      Citations:    
    58. Czepowicz VD, Johnson MR, Lydiard RB, Emmanuel NP, Ware MR, Mintzer OB, Walsh MD, Ballenger JC. Sertraline in social phobia. J Clin Psychopharmacol. 1995 Oct; 15(5):372-3. PMID: 8830070.
      Citations:    
    59. Katschnig H, Amering M, Stolk JM, Klerman GL, Ballenger JC, Briggs A, Buller R, Cassano G, Garvey M, Roth M, et al. Long-term follow-up after a drug trial for panic disorder. Br J Psychiatry. 1995 Oct; 167(4):487-94. PMID: 8829718.
      Citations:    
    60. Kramer MS, Cutler NR, Ballenger JC, Patterson WM, Mendels J, Chenault A, Shrivastava R, Matzura-Wolfe D, Lines C, Reines S. A placebo-controlled trial of L-365,260, a CCKB antagonist, in panic disorder. Biol Psychiatry. 1995 Apr 01; 37(7):462-6. PMID: 7786960.
      Citations:    
    61. Brewerton TD, Zealberg JJ, Lydiard RB, Glover V, Sandler M, Ballenger JC. CSF isatin is elevated in bulimia nervosa. Biol Psychiatry. 1995 Apr 01; 37(7):481-3. PMID: 7786964.
      Citations:    
    62. Katon W, Hollifield M, Chapman T, Mannuzza S, Ballenger J, Fyer A. Infrequent panic attacks: psychiatric comorbidity, personality characteristics and functional disability. J Psychiatr Res. 1995 Mar-Apr; 29(2):121-31. PMID: 7666380.
      Citations:    
    63. Brady KT, Sonne SC, Anton R, Ballenger JC. Valproate in the treatment of acute bipolar affective episodes complicated by substance abuse: a pilot study. J Clin Psychiatry. 1995 Mar; 56(3):118-21. PMID: 7883730.
      Citations:    
    64. Johnson MR, Lydiard RB, Ballenger JC. Panic disorder. Pathophysiology and drug treatment. Drugs. 1995 Mar; 49(3):328-44. PMID: 7774510.
      Citations:    
    65. Brewerton TD, Lydiard RB, Herzog DB, Brotman AW, O'Neil PM, Ballenger JC. Comorbidity of axis I psychiatric disorders in bulimia nervosa. J Clin Psychiatry. 1995 Feb; 56(2):77-80. PMID: 7852257.
      Citations:    
    66. Emmanuel NP, Lydiard RB, Reynolds RD, Roberts J, Johnson M, Mintzer O, Ballenger JC. Plasma pyridoxal phosphate in anxiety disorders. Biol Psychiatry. 1994 Nov 01; 36(9):606-8. PMID: 7833426.
      Citations:    
    67. Johnson MR, Lydiard RB, Zealberg JJ, Fossey MD, Ballenger JC. Plasma and CSF HVA levels in panic patients with comorbid social phobia. Biol Psychiatry. 1994 Sep 15; 36(6):425-7. PMID: 7803603.
      Citations:    
    68. Santos AB, Ballenger JC, Bevilacqua JJ, Zealberg JJ, Hiers TG, McLeod-Bryant S, Deci PA, Rames LJ. A community-based public-academic liaison program. Am J Psychiatry. 1994 Aug; 151(8):1181-7. PMID: 8037253.
      Citations:    
    69. Brawman-Mintzer O, Lydiard RB, Crawford MM, Emmanuel N, Payeur R, Johnson M, Knapp RG, Ballenger JC. Somatic symptoms in generalized anxiety disorder with and without comorbid psychiatric disorders. Am J Psychiatry. 1994 Jun; 151(6):930-2. PMID: 8185009.
      Citations:    
    70. Ballenger JC. Overview of panic disorder. Trans Am Clin Climatol Assoc. 1994; 105:36-51; discussion 51-3. PMID: 7974976.
      Citations:    
    71. Lydiard RB, Greenwald S, Weissman MM, Johnson J, Drossman DA, Ballenger JC. Panic disorder and gastrointestinal symptoms: findings from the NIMH Epidemiologic Catchment Area project. Am J Psychiatry. 1994 Jan; 151(1):64-70. PMID: 8267136.
      Citations:    
    72. Woodman CL, Noyes R, Ballenger JC, Lydiard RB, Sievers G, Mihalko D. Predictors of response to alprazolam and placebo in patients with panic disorder. J Affect Disord. 1994 Jan; 30(1):5-13. PMID: 8151049.
      Citations:    
    73. Ballenger JC, Pecknold J, Rickels K, Sellers EM. Medication discontinuation in panic disorder. J Clin Psychiatry. 1993 Oct; 54 Suppl:15-21; discussion 22-4. PMID: 8262887.
      Citations:    
    74. Brawman-Mintzer O, Lydiard RB, Emmanuel N, Payeur R, Johnson M, Roberts J, Jarrell MP, Ballenger JC. Psychiatric comorbidity in patients with generalized anxiety disorder. Am J Psychiatry. 1993 Aug; 150(8):1216-8. PMID: 8328567.
      Citations:    
    75. Lydiard RB, Brewerton TD, Fossey MD, Laraia MT, Stuart G, Beinfeld MC, Ballenger JC. CSF cholecystokinin octapeptide in patients with bulimia nervosa and in normal comparison subjects. Am J Psychiatry. 1993 Jul; 150(7):1099-101. PMID: 8317583.
      Citations:    
    76. Spiegel DA, Roth M, Weissman M, Lavori P, Gorman J, Rush J, Ballenger J. Comment on the London/Toronto Study of Alprazolam and Exposure in Panic Disorder with Agoraphobia. Br J Psychiatry. 1993 Jun; 162:788-9; discussion 790-4. PMID: 8101127.
      Citations:    
    77. Laird LK, Lydiard RB, Morton WA, Steele TE, Kellner C, Thompson NM, Ballenger JC. Cardiovascular effects of imipramine, fluvoxamine, and placebo in depressed outpatients. J Clin Psychiatry. 1993 Jun; 54(6):224-8. PMID: 8331091.
      Citations:    
    78. Lydiard RB, Fossey MD, Marsh W, Ballenger JC. Prevalence of psychiatric disorders in patients with irritable bowel syndrome. Psychosomatics. 1993 May-Jun; 34(3):229-34. PMID: 8493304.
      Citations:    
    79. Johnson MR, Lydiard RB, Morton WA, Laird LK, Steele TE, Kellner CH, Ballenger JC. Effect of fluvoxamine, imipramine and placebo on catecholamine function in depressed outpatients. J Psychiatr Res. 1993 Apr-Jun; 27(2):161-72. PMID: 8396179.
      Citations:    
    80. Stuart G, Laraia MT, Ballenger JC. Attending nurses. J Child Adolesc Psychiatr Ment Health Nurs. 1993 Apr-Jun; 6(2):38. PMID: 8340905.
      Citations:    
    81. Ballenger JC, Fyer AJ. Examining criteria for panic disorder. Hosp Community Psychiatry. 1993 Mar; 44(3):226-8. PMID: 8444431.
      Citations:    
    82. Fossey MD, Lydiard RB, Ballenger JC, Laraia MT, Bissette G, Nemeroff CB. Cerebrospinal fluid thyrotropin-releasing hormone concentrations in patients with anxiety disorders. J Neuropsychiatry Clin Neurosci. 1993; 5(3):335-7. PMID: 8369645.
      Citations:    
    83. Ballenger JC. Panic disorder: efficacy of current treatments. Psychopharmacol Bull. 1993; 29(4):477-86. PMID: 8084979.
      Citations:    
    84. Brewerton TD, Lydiard RB, Ballenger JC, Herzog DB. Eating disorders and social phobia. Arch Gen Psychiatry. 1993 Jan; 50(1):70. PMID: 8481194.
      Citations:    
    85. Lydiard RB, Morton WA, Emmanuel NP, Zealberg JJ, Laraia MT, Stuart GW, O'Neil PM, Ballenger JC. Preliminary report: placebo-controlled, double-blind study of the clinical and metabolic effects of desipramine in panic disorder. Psychopharmacol Bull. 1993; 29(2):183-8. PMID: 8290663.
      Citations:    
    86. Lesser IM, Lydiard RB, Antal E, Rubin RT, Ballenger JC, DuPont R. Alprazolam plasma concentrations and treatment response in panic disorder and agoraphobia. Am J Psychiatry. 1992 Nov; 149(11):1556-62. PMID: 1415824.
      Citations:    
    87. Payeur R, Lydiard RB, Ballenger JC, Laraia MT, Fossey MD, Zealberg J. CSF diazepam-binding inhibitor concentrations in panic disorder. Biol Psychiatry. 1992 Oct 15; 32(8):712-6. PMID: 1333825.
      Citations:    
    88. DuPont RL, Swinson RP, Ballenger JC, Burrows GD, Noyes R, Rubin RT, Rifkin A, Pecknold JC. Discontinuation of alprazolam after long-term treatment of panic-related disorders. J Clin Psychopharmacol. 1992 Oct; 12(5):352-4. PMID: 1479053.
      Citations:    
    89. Santos AB, Ballenger JC. Tricyclic antidepressant triggers mania in patient with organic affective disorder. J Clin Psychiatry. 1992 Oct; 53(10):377-8. PMID: 1429478.
      Citations:    
    90. Brewerton TD, Lydiard RB, Laraia MT, Shook JE, Ballenger JC. CSF beta-endorphin and dynorphin in bulimia nervosa. Am J Psychiatry. 1992 Aug; 149(8):1086-90. PMID: 1353317.
      Citations:    
    91. Villeponteaux VA, Lydiard RB, Laraia MT, Stuart GW, Ballenger JC. The effects of pregnancy on preexisting panic disorder. J Clin Psychiatry. 1992 Jun; 53(6):201-3. PMID: 1607348.
      Citations:    
    92. Lydiard RB, Ballenger JC, Laraia MT, Fossey MD, Beinfeld MC. CSF cholecystokinin concentrations in patients with panic disorder and in normal comparison subjects. Am J Psychiatry. 1992 May; 149(5):691-3. PMID: 1575262.
      Citations:    
    93. Lydiard RB, Lesser IM, Ballenger JC, Rubin RT, Laraia M, DuPont R. A fixed-dose study of alprazolam 2 mg, alprazolam 6 mg, and placebo in panic disorder. J Clin Psychopharmacol. 1992 Apr; 12(2):96-103. PMID: 1573046.
      Citations:    
    94. Ballenger JC. Medication discontinuation in panic disorder. J Clin Psychiatry. 1992 Mar; 53 Suppl:26-31. PMID: 1548252.
      Citations:    
    95. Emmanuel NP, Lydiard RB, Ballenger JC. Blood groups in panic disorder. Am J Psychiatry. 1992 Mar; 149(3):410. PMID: 1536283.
      Citations:    
    96. Jolley R, Lydiard RB, Assey ME, Usher BW, Barnwell WH, Ballenger JC. Cardiovascular status of panic disorder patients with and without prominent cardiac symptoms. Psychosomatics. 1992; 33(1):81-4. PMID: 1539107.
      Citations:    
    97. Ballenger JC, McDonald S, Noyes R, Rickels K, Woods SW, Patin J, Lydiard B, Garvey M, Cook B, Goodard AW, et al. The first double-blind, placebo-controlled trial of a partial benzodiazepine agonist, abecarnil (ZK 112-119), in generalized anxiety disorder. Adv Biochem Psychopharmacol. 1992; 47:431-47. PMID: 1354920.
      Citations:    
    98. Brady KT, Lydiard RB, Malcolm R, Ballenger JC. Cocaine-induced psychosis. J Clin Psychiatry. 1991 Dec; 52(12):509-12. PMID: 1752853.
      Citations:    
    99. Lydiard RB, Fossey MD, Ballenger JC. Irritable bowel syndrome in patients with panic disorder. Am J Psychiatry. 1991 Nov; 148(11):1614. PMID: 1928500.
      Citations:    
    100. Brady KT, Lydiard RB, Ballenger JC, Shook J, Laraia M, Fossey M. CSF opioids in panic disorder. Biol Psychiatry. 1991 Sep 01; 30(5):512-4. PMID: 1681945.
      Citations:    
    101. Austin LS, Lydiard RB, Ballenger JC, Cohen BM, Laraia MT, Zealberg JJ, Fossey MD, Ellinwood EH. Dopamine blocking activity of clomipramine in patients with obsessive-compulsive disorder. Biol Psychiatry. 1991 Aug 01; 30(3):225-32. PMID: 1832972.
      Citations:    
    102. Emmanuel NP, Lydiard RB, Ballenger JC. Treatment of social phobia with bupropion. J Clin Psychopharmacol. 1991 Aug; 11(4):276-7. PMID: 1918431.
      Citations:    
    103. Emmanuel NP, Lydiard RB, Ballenger JC. Fluoxetine treatment of voyeurism. Am J Psychiatry. 1991 Jul; 148(7):950. PMID: 2053642.
      Citations:    
    104. Melvin JA, Lydiard RB, Crowe CM, Laraia MT, Fossey MD, Ballenger JC. Effect of alprazolam on depression in panic disorder. J Clin Psychopharmacol. 1991 Apr; 11(2):145-6. PMID: 2056142.
      Citations:    
    105. Schatzberg AF, Ballenger JC. Decisions for the clinician in the treatment of panic disorder: when to treat, which treatment to use, and how long to treat. J Clin Psychiatry. 1991 Feb; 52 Suppl:26-31; discussion 32. PMID: 1995599.
      Citations:    
    106. Ballenger JC. Long-term pharmacologic treatment of panic disorder. J Clin Psychiatry. 1991 Feb; 52 Suppl:18-23; discussion 24-5. PMID: 1995598.
      Citations:    
    107. Ballenger JC, McDonald S, Noyes R, Rickels K, Sussman N, Woods S, Patin J, Singer J. The first double-blind, placebo-controlled trial of a partial benzodiazepine agonist abecarnil (ZK 112-119) in generalized anxiety disorder. Psychopharmacol Bull. 1991; 27(2):171-9. PMID: 1681563.
      Citations:    
    108. Kellner CH, Jolley RR, Holgate RC, Austin L, Lydiard RB, Laraia M, Ballenger JC. Brain MRI in obsessive-compulsive disorder. Psychiatry Res. 1991 Jan; 36(1):45-9. PMID: 2017522.
      Citations:    
    109. Malcolm R, Hutto BR, Phillips JD, Ballenger JC. Pergolide mesylate treatment of cocaine withdrawal. J Clin Psychiatry. 1991 Jan; 52(1):39-40. PMID: 1988417.
      Citations:    
    110. Zealberg JJ, Santos AB, Hiers TG, Ballenger JC, Puckett JA, Christie SD. From the benches to the trenches : training residents to provide emergency outreach services-a public/academic project. Acad Psychiatry. 1990 Dec; 14(4):211-7. PMID: 24436102.
      Citations:    
    111. Austin LS, Lydiard RB, Fossey MD, Zealberg JJ, Laraia MT, Ballenger JC. Panic and phobic disorders in patients with obsessive compulsive disorder. J Clin Psychiatry. 1990 Nov; 51(11):456-8. PMID: 2228980.
      Citations:    
    112. Brady K, Anton R, Ballenger JC, Lydiard RB, Adinoff B, Selander J. Cocaine abuse among schizophrenic patients. Am J Psychiatry. 1990 Sep; 147(9):1164-7. PMID: 2386250.
      Citations:    
    113. Austin LS, Arana GW, Ballenger JC. Rapid response of patients simultaneously treated with lithium and nortriptyline. J Clin Psychiatry. 1990 Mar; 51(3):124-5. PMID: 2407731.
      Citations:    
    114. Kaye WH, Ballenger JC, Lydiard RB, Stuart GW, Laraia MT, O'Neil P, Fossey MD, Stevens V, Lesser S, Hsu G. CSF monoamine levels in normal-weight bulimia: evidence for abnormal noradrenergic activity. Am J Psychiatry. 1990 Feb; 147(2):225-9. PMID: 1689122.
      Citations:    
    115. Stuart GW, Laraia MT, Ballenger JC, Lydiard RB. Early family experiences of women with bulimia and depression. Arch Psychiatr Nurs. 1990 Feb; 4(1):43-52. PMID: 2317098.
      Citations:    
    116. Ballenger JC. Efficacy of benzodiazepines in panic disorder and agoraphobia. J Psychiatr Res. 1990; 24 Suppl 2:15-25. PMID: 1980694.
      Citations:    
    117. Rifkin A, Pecknold JC, Swinson RP, Ballenger JC, Burrows GD, Noyes R, Dupont RL, Lesser I. Sequence of improvement in agoraphobia with panic attacks. J Psychiatr Res. 1990; 24(1):1-8. PMID: 2195163.
      Citations:    
    118. Lydiard RB, Laraia MT, Howell EF, Fossey MD, Reynolds RD, Ballenger JC. Phenelzine treatment of panic disorder: lack of effect on pyridoxal phosphate levels. J Clin Psychopharmacol. 1989 Dec; 9(6):428-31. PMID: 2687338.
      Citations:    
    119. Arana GW, Santos AB, Knax EP, Ballenger JC. Refractory rapid cycling unipolar depression responds to lithium and carbamazepine treatment. J Clin Psychiatry. 1989 Sep; 50(9):356-7. PMID: 2768205.
      Citations:    
    120. Lydiard RB, Howell EF, Laraia MT, Fossey MD, Ballenger JC. Depression in patients receiving lorazepam for panic. Am J Psychiatry. 1989 Sep; 146(9):1230-1. PMID: 2764184.
      Citations:    
    121. Ballenger JC, Carek DJ, Steele JJ, Cornish-McTighe D. Three cases of panic disorder with agoraphobia in children. Am J Psychiatry. 1989 Jul; 146(7):922-4. PMID: 2742019.
      Citations:    
    122. Anton RF, Ballenger JC, Lydiard RB, Laraia MT, Howell EF, Gold PW. CSF prostaglandin-E in agoraphobia with panic attacks. Biol Psychiatry. 1989 Jul; 26(3):257-64. PMID: 2545288.
      Citations:    
    123. Malcolm R, Ballenger JC, Sturgis ET, Anton R. Double-blind controlled trial comparing carbamazepine to oxazepam treatment of alcohol withdrawal. Am J Psychiatry. 1989 May; 146(5):617-21. PMID: 2653057.
      Citations:    
    124. Ballenger JC. Toward an integrated model of panic disorder. Am J Orthopsychiatry. 1989 Apr; 59(2):284-93. PMID: 2653050.
      Citations:    
    125. Lydiard RB, Laird LK, Morton WA, Steele TE, Kellner C, Laraia MT, Ballenger JC. Fluvoxamine, imipramine, and placebo in the treatment of depressed outpatients: effects on depression. Psychopharmacol Bull. 1989; 25(1):68-70. PMID: 2505304.
      Citations:    
    126. Lesser IM, Rubin RT, Rifkin A, Swinson RP, Ballenger JC, Burrows GD, Dupont RL, Noyes R, Pecknold JC. Secondary depression in panic disorder and agoraphobia. II. Dimensions of depressive symptomatology and their response to treatment. J Affect Disord. 1989 Jan-Feb; 16(1):49-58. PMID: 2521651.
      Citations:    
    127. Lydiard RB, Zealberg J, Laraia MT, Fossey M, Prockow V, Gross J, Ballenger JC. Electroencephalography during sleep of patients with panic disorder. J Neuropsychiatry Clin Neurosci. 1989; 1(4):372-6. PMID: 2521085.
      Citations:    
    128. Lydiard RB, Roy-Byrne PP, Ballenger JC. Recent advances in the psychopharmacological treatment of anxiety disorders. Hosp Community Psychiatry. 1988 Nov; 39(11):1157-65. PMID: 2906319.
      Citations:    
    129. Ballenger JC. The use of anticonvulsants in manic-depressive illness. J Clin Psychiatry. 1988 Nov; 49 Suppl:21-5. PMID: 3053672.
      Citations:    
    130. Lydiard RB, Laraia MT, Fossey M, Ballenger JC. Possible relationship of bowel obsessions to panic disorder with agoraphobia. Am J Psychiatry. 1988 Oct; 145(10):1324-5. PMID: 3421372.
      Citations:    
    131. Santos AB, Thrasher JW, Ballenger JC. Decentralized services for public hospital patients: a cost analysis. Hosp Community Psychiatry. 1988 Aug; 39(8):827-9. PMID: 3209197.
      Citations:    
    132. Cox DJ, Ballenger JC, Laraia M, Hobbs WR, Peterson GA, Hucek A. Different rates of improvement of different symptoms in combined pharmacological and behavioral treatment of agoraphobia. J Behav Ther Exp Psychiatry. 1988 Jun; 19(2):119-26. PMID: 3209696.
      Citations:    
    133. Noyes R, DuPont RL, Pecknold JC, Rifkin A, Rubin RT, Swinson RP, Ballenger JC, Burrows GD. Alprazolam in panic disorder and agoraphobia: results from a multicenter trial. II. Patient acceptance, side effects, and safety. Arch Gen Psychiatry. 1988 May; 45(5):423-8. PMID: 3358644.
      Citations:    
    134. Ballenger JC, Burrows GD, DuPont RL, Lesser IM, Noyes R, Pecknold JC, Rifkin A, Swinson RP. Alprazolam in panic disorder and agoraphobia: results from a multicenter trial. I. Efficacy in short-term treatment. Arch Gen Psychiatry. 1988 May; 45(5):413-22. PMID: 3282478.
      Citations:    
    135. Ballenger JC. The clinical use of carbamazepine in affective disorders. J Clin Psychiatry. 1988 Apr; 49 Suppl:13-21. PMID: 3280557.
      Citations:    
    136. Brown ME, Anton RF, Malcolm R, Ballenger JC. Alcohol detoxification and withdrawal seizures: clinical support for a kindling hypothesis. Biol Psychiatry. 1988 Mar 01; 23(5):507-14. PMID: 3345323.
      Citations:    
    137. Lydiard RB, Laraia MT, Howell EF, Ballenger JC. Alprazolam in the treatment of social phobia. J Clin Psychiatry. 1988 Jan; 49(1):17-9. PMID: 3335485.
      Citations:    
    138. Lydiard RB, Brady KT, O'Neil PM, Schlesier-Carter B, Hamilton S, Rogers Q, Ballenger JC. Precursor amino acid concentrations in normal weight bulimics and normal controls. Prog Neuropsychopharmacol Biol Psychiatry. 1988; 12(6):893-8. PMID: 3241872.
      Citations:    
    139. Ballenger JC. Unrecognized prevalence of panic disorder in primary care, internal medicine and cardiology. Am J Cardiol. 1987 Dec 28; 60(18):39J-47J. PMID: 3321969.
      Citations:    
    140. Lydiard RB, Ballenger JC. Antidepressants in panic disorder and agoraphobia. J Affect Disord. 1987 Sep-Oct; 13(2):153-68. PMID: 2960710.
      Citations:    
    141. Lydiard RB, Laraia MT, Ballenger JC, Howell EF. Emergence of depressive symptoms in patients receiving alprazolam for panic disorder. Am J Psychiatry. 1987 May; 144(5):664-5. PMID: 3578580.
      Citations:    
    142. Lydiard RB, Howell EF, Laraia MT, Ballenger JC. Sexual side effects of alprazolam. Am J Psychiatry. 1987 Feb; 144(2):254-5. PMID: 3812806.
      Citations:    
    143. Lydiard RB, Laraia MT, Howell EF, Ballenger JC. Can panic disorder present as irritable bowel syndrome? J Clin Psychiatry. 1986 Sep; 47(9):470-3. PMID: 3745130.
      Citations:    
    144. Post RM, Rubinow DR, Ballenger JC. Conditioning and sensitisation in the longitudinal course of affective illness. Br J Psychiatry. 1986 Aug; 149:191-201. PMID: 3535979.
      Citations:    
    145. Ballenger JC. Pharmacotherapy of the panic disorders. J Clin Psychiatry. 1986 Jun; 47 Suppl:27-32. PMID: 2872207.
      Citations:    
    146. Joffe RT, Post RM, Ballenger JC, Rebar R, Gold PW. The effects of lithium on neuroendocrine function in affectively ill patients. Acta Psychiatr Scand. 1986 May; 73(5):524-8. PMID: 3092580.
      Citations:    
    147. Ballenger JC. Biological aspects of panic disorder. Am J Psychiatry. 1986 Apr; 143(4):516-8. PMID: 3953894.
      Citations:    
    148. Post RM, Rubinow DR, Uhde TW, Ballenger JC, Linnoila M. Dopaminergic effects of carbamazepine. Relationship to clinical response in affective illness. Arch Gen Psychiatry. 1986 Apr; 43(4):392-6. PMID: 3954558.
      Citations:    
    149. Joffe RT, Post RM, Ballenger JC, Rebar R, Gold PW. Neuroendocrine effects of carbamazepine in patients with affective illness. Epilepsia. 1986 Mar-Apr; 27(2):156-60. PMID: 3082622.
      Citations:    
    150. Joffe RT, Post RM, Ballenger JC, Rebar R, Rakita R, Gold PW. Neuroendocrine effects of the dopamine agonist piribedil in depressed patients. Clin Neuropharmacol. 1986; 9(5):448-55. PMID: 3768867.
      Citations:    
    151. Peterson GA, Ballenger JC, Cox DP, Hucek A, Lydiard RB, Laraia MT, Trockman C. The dexamethasone suppression test in agoraphobia. J Clin Psychopharmacol. 1985 Apr; 5(2):100-2. PMID: 3988966.
      Citations:    
    152. Rubinow DR, Post RM, Gold PW, Ballenger JC, Reichlin S. Effects of carbamazepine on cerebrospinal fluid somatostatin. Psychopharmacology (Berl). 1985; 85(2):210-3. PMID: 2861620.
      Citations:    
    153. Rubinow DR, Gold PW, Post RM, Ballenger JC. CSF somatostatin in affective illness and normal volunteers. Prog Neuropsychopharmacol Biol Psychiatry. 1985; 9(4):393-400. PMID: 2866561.
      Citations:    
    154. Post RM, Rubinow DR, Uhde TW, Ballenger JC, Lake CR, Linnoila M, Jimerson DC, Reus V. Effects of carbamazepine on noradrenergic mechanisms in affectively ill patients. Psychopharmacology (Berl). 1985; 87(1):59-63. PMID: 2997829.
      Citations:    
    155. Ballenger JC. Psychopharmacology of the anxiety disorders. Psychiatr Clin North Am. 1984 Dec; 7(4):757-71. PMID: 6151647.
      Citations:    
    156. Vieweg WV, Yazel JJ, Ballenger JC. Tricyclic antidepressant use in a patient with bundle branch blocks and ventricular ectopy. J Clin Psychiatry. 1984 Aug; 45(8):353-5. PMID: 6204970.
      Citations:    
    157. Post RM, Uhde TW, Ballenger JC. The efficacy of carbamazepine in affective illness. Adv Biochem Psychopharmacol. 1984; 39:421-37. PMID: 6380232.
      Citations:    
    158. Zuckerman M, Ballenger JC, Post RM. The neurobiology of some dimensions of personality. Int Rev Neurobiol. 1984; 25:391-436. PMID: 6469473.
      Citations:    
    159. Ballenger JC, Post RM. Carbamazepine in alcohol withdrawal syndromes and schizophrenic psychoses. Psychopharmacol Bull. 1984; 20(3):572-84. PMID: 6382378.
      Citations:    
    160. Post RM, Uhde TW, Ballenger JC, Squillace KM. Prophylactic efficacy of carbamazepine in manic-depressive illness. Am J Psychiatry. 1983 Dec; 140(12):1602-4. PMID: 6139957.
      Citations:    
    161. Gold PW, Robertson GL, Ballenger JC, Kaye W, Chen J, Rubinow DR, Goodwin FK, Post RM. Carbamazepine diminishes the sensitivity of the plasma arginine vasopressin response to osmotic stimulation. J Clin Endocrinol Metab. 1983 Nov; 57(5):952-7. PMID: 6619270.
      Citations:    
    162. Kellner CH, Rakita RM, Rubinow DA, Gold PW, Ballenger JC, Post RM. Tetrahydrobiopterin levels in cerebrospinal fluid of affectively ill patients. Lancet. 1983 Jul 02; 2(8340):55-6. PMID: 6134926.
      Citations:    
    163. Sternberg DE, van Kammen DP, Lerner P, Ballenger JC, Marder SR, Post RM, Bunney WE. CSF dopamine beta-hydroxylase in schizophrenia. Arch Gen Psychiatry. 1983 Jul; 40(7):743-7. PMID: 6134515.
      Citations:    
    164. Post RM, Uhde TW, Ballenger JC, Chatterji DC, Greene RF, Bunney WE. Carbamazepine and its -10,11-epoxide metabolite in plasma and CSF. Relationship to antidepressant response. Arch Gen Psychiatry. 1983 Jun; 40(6):673-6. PMID: 6847334.
      Citations:    
    165. Post RM, Ballenger JC, Putnam FW, Bunney WE. Carbamazepine in alcohol withdrawal syndromes: relationship to the kindling model. J Clin Psychopharmacol. 1983 Jun; 3(3):204-5. PMID: 6875029.
      Citations:    
    166. Rubinow DR, Gold PW, Post RM, Ballenger JC, Cowdry R, Bollinger J, Reichlin S. CSF somatostatin in affective illness. Arch Gen Psychiatry. 1983 Apr; 40(4):409-12. PMID: 6132592.
      Citations:    
    167. Gold PW, Robertson GL, Post RM, Kaye W, Ballenger J, Rubinow D, Goodwin FK. The effect of lithium on the osmoregulation of arginine vasopressin secretion. J Clin Endocrinol Metab. 1983 Feb; 56(2):295-9. PMID: 6401749.
      Citations:    
    168. Post RM, Uhde TW, Rubinow DR, Ballenger JC, Gold PW. Biochemical effects of carbamazepine: relationship to its mechanisms of action in affective illness. Prog Neuropsychopharmacol Biol Psychiatry. 1983; 7(2-3):263-71. PMID: 6137029.
      Citations:    
    169. Gold PW, Robertson GL, Ballenger JC, Goodwin FK, Rubinow DR, Kellner C, Post RM. Neurohypophyseal function in affective illness. Psychopharmacol Bull. 1983; 19(3):426-31. PMID: 6635117.
      Citations:    
    170. Rubinow DR, Gold PW, Post RM, Ballenger JC, Reichlin S. Cerebrospinal fluid somatostatin in primary affective disorder. Psychopharmacol Bull. 1983; 19(3):422-5. PMID: 6138797.
      Citations:    
    171. Post RM, Uhde TW, Putnam FW, Ballenger JC, Berrettini WH. Kindling and carbamazepine in affective illness. J Nerv Ment Dis. 1982 Dec; 170(12):717-31. PMID: 6754868.
      Citations:    
    172. Shemo JP, Ballenger JC, Yazel JJ, Spradlin WW. A conjoint psychiatry-internal medicine program: development of a teaching and clinical model. Am J Psychiatry. 1982 Nov; 139(11):1437-42. PMID: 7137393.
      Citations:    
    173. Post RM, Ballenger JC, Uhde TW, Smith C, Rubinow DR, Bunney WE. Effect of carbamazepine on cyclic nucleotides in CSF of patients with affective illness. Biol Psychiatry. 1982 Sep; 17(9):1037-45. PMID: 6291645.
      Citations:    
    174. Post RM, Gold P, Rubinow DR, Ballenger JC, Bunney WE, Goodwin FK. Peptides in the cerebrospinal fluid of neuropsychiatric patients: an approach to central nervous system peptide function. Life Sci. 1982 Jul 05; 31(1):1-15. PMID: 6180277.
      Citations:    
    175. Ballenger JC, Reus VI, Post RM. The "atypical" clinical picture of adolescent mania. Am J Psychiatry. 1982 May; 139(5):602-6. PMID: 7072845.
      Citations:    
    176. Garbutt JC, van Kammen DP, Levine RA, Sternberg DE, Murphy DL, Ballenger J, Bunney WE, Lovenberg WM. Cerebrospinal fluid hydroxylase cofactor in schizophrenia. Psychiatry Res. 1982 Apr; 6(2):145-51. PMID: 6953456.
      Citations:    
    177. Hare TA, Wood JH, Manyam BV, Gerner RH, Ballenger JC, Post RM. Central nervous system gamma-aminobutyric acid activity in man. Relationship to age and sex as reflected in CSF. Arch Neurol. 1982 Apr; 39(4):247-9. PMID: 7073535.
      Citations:    
    178. Pickar D, Naber D, Post RM, van Kammen DP, Kaye W, Rubinow DR, Ballenger JC, Bunney WE. Endorphins in the cerebrospinal fluid of psychiatric patients. Ann N Y Acad Sci. 1982; 398:399-412. PMID: 6297360.
      Citations:    
    179. Paul SM, Rehavi M, Skolnick P, Ballenger JC, Goodwin FK. Depressed patients have decreased binding of tritiated imipramine to platelet serotonin "transporter". Arch Gen Psychiatry. 1981 Dec; 38(12):1315-7. PMID: 7316676.
      Citations:    
    180. Naber D, Pickar D, Post RM, Van Kammen DP, Waters RN, Ballenger JC, Goodwin FK, Bunney WE. Endogenous opioid activity and beta-endorphin immunoreactivity in CSF of psychiatric patients and normal volunteers. Am J Psychiatry. 1981 Nov; 138(11):1457-62. PMID: 6271019.
      Citations:    
    181. Rubinow DR, Post RM, Pickar D, Naber D, Ballenger JC, Gold PW, Bunney WE. Relationship between urinary free cortisol and CSF opioid binding activity in depressed patients and normal volunteers. Psychiatry Res. 1981 Aug; 5(1):87-93. PMID: 6269142.
      Citations:    
    182. Sternberg DE, van Kammen DP, Lake CR, Ballenger JC, Marder SR, Bunney WE. The effect of pimozide on CSF norepinephrine in schizophrenia. Am J Psychiatry. 1981 Aug; 138(8):1045-50. PMID: 7258379.
      Citations:    
    183. Post RM, Pickar D, Naber D, Ballenger JC, Uhde TW, Bunney WE. Effect of carbamazepine on CSF opioid activity; relationship to antidepressant response. Psychiatry Res. 1981 Aug; 5(1):59-66. PMID: 6269141.
      Citations:    
    184. Post RM, Ballenger JC, Rey AC, Bunney WE. Slow and rapid onset of manic episodes: implications for underlying biology. Psychiatry Res. 1981 Apr; 4(2):229-37. PMID: 6939012.
      Citations:    
    185. Weingartner H, Gold P, Ballenger JC, Smallberg SA, Summers R, Rubinow DR, Post RM, Goodwin FK. Effects of vasopressin on human memory functions. Science. 1981 Feb 06; 211(4482):601-3. PMID: 7455701.
      Citations:    
    186. Pickar D, Naber D, Post RM, van Kammen DP, Ballenger J, Kalin N, Bunney WE. Measurement of endorphins in CSF. Relationship to psychiatric diagnosis. Mod Probl Pharmacopsychiatry. 1981; 17:246-62. PMID: 7329420.
      Citations:    
    187. Brown GL, Goodwin FK, Ballenger JC, Goyer PF. Cerebrospinal fluid amine metabolites and cyclic nucleotides in human aggression [proceedings]. Psychopharmacol Bull. 1981 Jan; 17(1):63-5. PMID: 6165032.
      Citations:    
    188. Jimerson DC, Ballenger JC, Lake CR, Post RM, Goodwin FK, Kopin IJ. Plasma and CSF MHPG in normals [proceedings]. Psychopharmacol Bull. 1981 Jan; 17(1):86-7. PMID: 7232666.
      Citations:    
    189. Post RM, Ballenger JC, Hare TA, Bunney WE. Lack of effect of carbamazepine on gamma-aminobutyric acid in cerebrospinal fluid. Neurology. 1980 Sep; 30(9):1008-11. PMID: 7191529.
      Citations:    
    190. Becker KL, Silva OL, Post RM, Ballenger JC, Carman JS, Snider RH, Moore CF. Immunoreactive calcitonin in cerebrospinal fluid of man. Brain Res. 1980 Aug 04; 194(2):598-602. PMID: 7388636.
      Citations:    
    191. Ballenger JC, Post RM. Carbamazepine in manic-depressive illness: a new treatment. Am J Psychiatry. 1980 Jul; 137(7):782-90. PMID: 7386656.
      Citations:    
    192. Major LF, Lerner P, Goodwin FK, Ballenger JC, Brown GL, Lovenberg W. Dopamine beta-hydroxylase in CSF. Relationship to personality measures. Arch Gen Psychiatry. 1980 Mar; 37(3):308-10. PMID: 7362418.
      Citations:    
    193. Gold PW, Extein I, Ballenger JC, Wehr TA. Rapid mood cycling and concomitant cortisol changes produced by cyproheptadine. Am J Psychiatry. 1980 Mar; 137(3):378-9. PMID: 7356073.
      Citations:    
    194. Lake CR, Sternberg DE, van Kammen DP, Ballenger JC, Ziegler MG, Post RM, Kopin IJ, Bunney WE. Schizophrenia: elevated cerebrospinal fluid norepinephrine. Science. 1980 Jan 18; 207(4428):331-3. PMID: 7350667.
      Citations:    
    195. Sheehan DV, Ballenger J, Jacobsen G. Treatment of endogenous anxiety with phobic, hysterical, and hypochondriacal symptoms. Arch Gen Psychiatry. 1980 Jan; 37(1):51-9. PMID: 7352840.
      Citations:    
    196. Gold PW, Weingartner H, Ballenger JC, Goodwin FK, Post RM. Effects of 1-desamo-8-D-arginine vasopressin on behaviour and cognition in primary affective disorder. Lancet. 1979 Nov 10; 2(8150):992-4. PMID: 91778.
      Citations:    
    197. Brown GL, Goodwin FK, Ballenger JC, Goyer PF, Major LF. Aggression in humans correlates with cerebrospinal fluid amine metabolites. Psychiatry Res. 1979 Oct; 1(2):131-9. PMID: 95232.
      Citations:    
    198. Hare TA, Wood JH, Ballenger JC, Post RM. gamma-Aminobutyric acid in human cerebrospinal fluid: normal values. Lancet. 1979 Sep 08; 2(8141):534-5. PMID: 90262.
      Citations:    
    199. Wood JH, Hare TA, Glaeser BS, Ballenger JC, Post RM. Low cerebrospinal fluid gamma-aminobutyric acid content in seizure patients. Neurology. 1979 Sep; 29(9 Pt 1):1203-8. PMID: 113694.
      Citations:    
    200. Ballenger JC, Post RM, Sternberg DE, Van Kammen DP, Cowdry RW, Goodwin FK. Headaches after lumbar puncture and insensitivity to pain in psychiatric patients. N Engl J Med. 1979 Jul 12; 301(2):110. PMID: 449939.
      Citations:    
    201. Major LF, Lerner P, Ballenger JC, Brown GL, Goodwin FK, Lovenberg W. Dopamine-beta-hydroxylase in the cerebrospinal fluid: relationship to disulfiram-induced psychosis. Biol Psychiatry. 1979 Apr; 14(2):337-44. PMID: 476222.
      Citations:    
    202. Ballenger JC, Goodwin FK, Major LF, Brown GL. Alcohol and central serotonin metabolism in man. Arch Gen Psychiatry. 1979 Feb; 36(2):224-7. PMID: 420544.
      Citations:    
    203. Lerner P, Goodwin FK, van Kammen DP, Post RM, Major LF, Ballenger JC, Lovenberg W. Dopamine-beta-hydroxylase in the cerebrospinal fluid of psychiatric patients. Biol Psychiatry. 1978 Dec; 13(6):685-94. PMID: 737256.
      Citations:    
    204. Ballenger JC, Post RM. Kindling as a model for alcohol withdrawal syndromes. Br J Psychiatry. 1978 Jul; 133:1-14. PMID: 352467.
      Citations:    
    205. Ballenger JC, Post RM. Therapeutic effects of carbamazepine in affective illness: a preliminary report. Commun Psychopharmacol. 1978; 2(2):159-75. PMID: 352607.
      Citations:    
    206. Major LF, Ballenger JC, Goodwin FK, Brown GL. Cerebrospinal fluid homovanillic acid in male alcoholics: effects of disulfiram. Biol Psychiatry. 1977 Oct; 12(5):635-42. PMID: 588644.
      Citations:    
    207. Ballenger JC. Electroconvulsive therapy and cardiac pacemakers. Psychosomatics. 1973 Jul-Aug; 14(4):233-4. PMID: 4794928.
      Citations:    
    Ballenger's Networks
    Click the
    Explore
    buttons for more information and interactive visualizations!
    Concepts (501)
    Explore
    _
    Co-Authors (27)
    Explore
    _
    Similar People (60)
    Explore
    _
    Same Department Expand Description
    Explore
    _